What Is Neurotrophin-3? Definition and What Research Reports
Neurotrophin-3 (NT-3) is a small secreted protein in the neurotrophin growth-factor family, alongside NGF and BDNF. It signals mainly through the TrkC receptor and p75NTR, and is produced by neurons, glia and several non-neural tissues. Published work has described NT-3 in synaptic transmission, retinal photoreceptor survival, liver homeostasis, endothelial repair, memory formation, schizophrenia biomarkers, tumour biology, and as a payload in cochlear delivery and nerve-scaffold studies.
Definition
Neurotrophin-3 (NT-3) is a small secreted signalling protein belonging to the neurotrophin family of growth factors, a group that also includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5. Like other neurotrophins, NT-3 is synthesised as a precursor (proNT-3) that is processed to a mature, disulphide-linked dimeric protein. Its principal high-affinity receptor is the tyrosine kinase receptor TrkC, with lower-affinity interactions at TrkA, TrkB and the p75 neurotrophin receptor. NT-3 is expressed by neurons and glia in the central and peripheral nervous systems, and also by non-neural cells including retinal Müller cells and hepatic stellate cells. In the laboratory literature it is used as a recombinant protein tool for studying neuronal survival, synaptic function, tissue repair and receptor pharmacology, rather than as a short synthetic peptide.
What Class of Molecule Is It?
NT-3 is a protein growth factor, not a synthetic peptide analogue. Mature neurotrophins are roughly 120 amino acids per monomer and function as non-covalent homodimers. Because of this size and its dependence on correct folding and dimerisation, NT-3 used in research is typically produced recombinantly rather than by solid-phase synthesis, which distinguishes it from the shorter research peptides that are often catalogued alongside it.
Where It Comes From in the Body
- Nervous system: neurons and supporting glial cells express NT-3, which acts on TrkC-bearing targets.
- Retina: Müller glial cells were identified as a source of NT-3 acting on photoreceptors in a hypoxia model (PMID 31768729).
- Liver: hepatic stellate cells were reported to produce NT-3 as a paracrine signal to hepatocytes (PMID 37253090).
- Airway and other epithelia: NT-3 levels have been measured in tissue samples such as nasal polyps (PMID 29974835).
How the Term Is Used in Peptide and Growth-Factor Research
In published research, "neurotrophin-3" usually refers to one of three things: the endogenous protein measured as a biomarker in blood or tissue; recombinant NT-3 applied to cells or delivered to a tissue compartment in animal experiments; or the NTF3 gene and its polymorphisms in genetic association studies. The literature spans neuroscience, ophthalmology, hepatology, oncology and biomaterials engineering, so the same term appears in very different experimental contexts.
Common Research Contexts
| Context | What researchers examined | Example citation |
|---|---|---|
| Synaptic function | NT-3 as a modulator of synaptic transmission | PMID 32723551 |
| Retina | Glia-derived NT-3 and photoreceptor apoptosis under hypoxia | PMID 31768729 |
| Liver | Paracrine NT-3 signalling and hepatocyte proliferation | PMID 37253090 |
| Vascular repair | Endothelial progenitor cell mobilisation and reendothelialisation | PMID 33817212 |
| Psychiatry | Serum NT-3 and NTF3 polymorphisms in schizophrenia spectrum disorder | PMID 35873610 |
| Oncology | NT-3 and stemness properties in lung cancer | PMID 38885623 |
| Delivery science | Pharmacokinetics after intracochlear or supraparticle delivery | PMID 30790594 |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
A 2020 review in Vitamins and Hormones summarised evidence that NT-3 modulates synaptic transmission, positioning the protein as a regulator of neuronal communication rather than only a survival factor (PMID 32723551). In a 2023 Science Signaling report, researchers described hepatic stellate cells maintaining liver homeostasis through paracrine neurotrophin-3 signalling that induced hepatocyte proliferation, extending NT-3 biology well beyond the nervous system (PMID 37253090). A 2020 cell-culture study reported that Müller cell–derived NT-3 inhibited hypoxia-induced photoreceptor apoptosis via the TrkC/ERK pathway, identifying a specific receptor-to-kinase route for the effect (PMID 31768729).
Vascular and Behavioural Findings
A 2020 report in Open Life Sciences found that NT-3 accelerated reendothelialisation by inducing endothelial progenitor cell mobilisation and homing in an experimental injury model (PMID 33817212). On the behavioural side, a 2024 study in Behavioural Brain Research reported that neurotrophin-3 delivered into the insular cortex strengthened conditioned taste aversion memory in rodents, linking local NT-3 availability to memory consolidation in a defined brain region (PMID 38211776).
Clinical Measurement and Genetics
NT-3 also appears as a measured analyte in clinical samples. A 2022 study in the Indian Journal of Clinical Biochemistry reported that risperidone treatment was associated with reduced matrix metalloproteinase-9 and increased neurotrophin-3 in patients with schizophrenia spectrum of disorder (PMID 35873610). A separate 2023 report examined neurotrophin-3 gene polymorphism in schizophrenia and its relation to disease severity and cognitive dysfunction (PMID 37692806). In otolaryngology, a 2018 study asked whether NT-3 had any effect on the pathogenesis of non-allergic nasal polyps (PMID 29974835). Not all NT-3 associations reported in the literature are framed as favourable: a 2024 paper in Neuroendocrinology reported that neurotrophin-3 facilitated stemness properties and was associated with poor survival in lung cancer (PMID 38885623).
Delivery and Formulation Research
Because NT-3 is a protein that does not cross biological barriers freely, a distinct strand of the literature concerns how it is delivered. A 2019 paper in the Journal of Controlled Release characterised the pharmacokinetics and tissue distribution of neurotrophin-3 after intracochlear delivery (PMID 30790594), and a 2022 follow-up in the same journal reported pharmacokinetics and biodistribution of supraparticle-delivered neurotrophin-3 in the guinea pig cochlea (PMID 34999140). In regenerative engineering, a study on freeze-cast chitosan–alginate nerve-guidance scaffolds examined strategies for the release of neurotrophin-3 together with chondroitinase ABC (PMID 24889394). These papers are about formulation and local exposure in animal or benchtop systems, not about human administration.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appSafety and Tolerability: What Studies Report
The verified studies summarised here were predominantly mechanistic, biomarker or delivery investigations, and their published abstracts focused on signalling pathways, tissue distribution and disease associations rather than on systematic adverse-event reporting. One caution that emerges directly from the literature is biological rather than procedural: researchers reported that NT-3 facilitated stemness properties and was associated with poor survival in lung cancer, indicating that NT-3 signalling is not uniformly beneficial across tissues (PMID 38885623). Delivery studies such as the cochlear pharmacokinetic work characterised where the protein went and how long it persisted rather than establishing a safety profile (PMID 34999140). No human safety conclusions can be drawn from this set of papers.
Regulatory Status
Recombinant neurotrophin-3 is supplied for laboratory and research use only. There is no approved neurotrophin-3 drug product in the United States, and the studies cited on this page were conducted in cell systems, animal models or as clinical measurements of endogenous NT-3 levels and genotypes rather than as trials of an NT-3 medicine.
This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition, medication or investigational compound.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Neurotrophin-3 modulates synaptic transmission (Vitamins and Hormones, 2020)
- Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation (Science Signaling, 2023)
- Neurotrophin-3 accelerates reendothelialization through inducing EPC mobilization and homing (Open Life Sciences, 2020)
- Neurotrophin-3 Facilitates Stemness Properties and Associates with Poor Survival in Lung Cancer (Neuroendocrinology, 2024)
- Is there any effect of neurotrophin-3 on the pathogenesis of non-allergic nasal polyps? (The Journal of Laryngology and Otology, 2018)
- Pharmacokinetics and tissue distribution of neurotrophin 3 after intracochlear delivery (Journal of Controlled Release, 2019)
- Müller cells derived neurotrophin-3 inhibits hypoxia-induced photoreceptor apoptosis via the TrkC/ERK pathway (Cytotechnology, 2020)
- Risperidone Reduces Matrix Metalloproteinase-9 and Increases Neurotrophin-3 in Schizophrenia Spectrum of Disorder (Indian Journal of Clinical Biochemistry, 2022)
- Neurotrophin-3 into the insular cortex strengthens conditioned taste aversion memory (Behavioural Brain Research, 2024)
- Neurotrophin-3 gene polymorphism in schizophrenia and its relation with diseases severity and cognitive dysfunction (Journal of Neurosciences in Rural Practice, 2023)
- Strategies for neurotrophin-3 and chondroitinase ABC release from freeze-cast chitosan-alginate nerve-guidance scaffolds (Journal of Tissue Engineering and Regenerative Medicine, 2017)
- Pharmacokinetics and biodistribution of supraparticle-delivered neurotrophin 3 in the guinea pig cochlea (Journal of Controlled Release, 2022)
Frequently asked questions
Is neurotrophin-3 a peptide or a protein?▾
NT-3 is a protein growth factor rather than a short synthetic peptide. It belongs to the neurotrophin family with NGF and BDNF, is produced as a precursor and functions as a dimer. Research material is recombinant. A 2020 review described its role in modulating synaptic transmission (PMID 32723551), reflecting its classification as a signalling protein.
Which receptor does neurotrophin-3 signal through?▾
Its principal high-affinity receptor is the tyrosine kinase TrkC, with lower-affinity binding at other Trk receptors and p75NTR. A 2020 cell study reported that Müller cell–derived NT-3 inhibited hypoxia-induced photoreceptor apoptosis via the TrkC/ERK pathway (PMID 31768729), illustrating one downstream route researchers have mapped experimentally.
Does neurotrophin-3 act outside the nervous system?▾
Yes. A 2023 study reported that hepatic stellate cells maintained liver homeostasis through paracrine neurotrophin-3 signalling that induced hepatocyte proliferation (PMID 37253090). A 2020 report also found NT-3 accelerated reendothelialisation by inducing endothelial progenitor cell mobilisation and homing (PMID 33817212), indicating roles in liver and vascular biology.
Has neurotrophin-3 been studied as a biomarker?▾
It has. Researchers reported that risperidone treatment reduced matrix metalloproteinase-9 and increased neurotrophin-3 in schizophrenia spectrum of disorder (PMID 35873610), and a separate study examined NT-3 gene polymorphism in schizophrenia in relation to disease severity and cognitive dysfunction (PMID 37692806). NT-3 was also measured in non-allergic nasal polyp tissue (PMID 29974835).
Are there findings that complicate the picture?▾
Yes. A 2024 study reported that neurotrophin-3 facilitated stemness properties and was associated with poor survival in lung cancer (PMID 38885623). That finding shows NT-3 signalling is not uniformly favourable and that its effects depend on tissue and disease context, which is why the literature is read case by case rather than generalised.
Why do researchers study NT-3 delivery systems?▾
Because NT-3 is a protein that does not distribute freely across barriers, delivery is a research problem in itself. Studies characterised pharmacokinetics and tissue distribution after intracochlear delivery (PMID 30790594) and after supraparticle delivery in the guinea pig cochlea (PMID 34999140), while other work examined release from chitosan-alginate nerve-guidance scaffolds (PMID 24889394).
Is neurotrophin-3 an approved medicine?▾
No. Recombinant NT-3 is supplied for research use only, and there is no approved neurotrophin-3 drug product in the United States. The published work cited here consists of cell studies, animal models, biomarker measurements and delivery characterisation, such as the insular cortex memory study in rodents (PMID 38211776), not approval trials.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.